) recently announced that Aspen Global Inc., a subsidiary of
Aspen Pharmacare Holdings Limited, has offered to buy Glaxo's
thrombosis brands. Aspen Pharma has also offered to purchase the
related manufacturing site in France, Notre-Dame de Bondeville.
The financial terms of the deal were not disclosed.
BIOGEN IDEC INC (BIIB): Free Stock Analysis
GLAXOSMITHKLINE (GSK): Free Stock Analysis
NOVO-NORDISK AS (NVO): Free Stock Analysis
SANTARUS INC (SNTS): Free Stock Analysis
To read this article on Zacks.com click here.
Glaxo's thrombosis brands include Arixtra and Fraxiparine. In the
first quarter of 2013, Arixtra and Fraxiparine generated sales of
£49 million (up 2% from the year-ago quarter) and £52 million
(down 16% from the year-ago quarter), respectively. The proposed
deal does not include right to the drugs in China, India and
Glaxo and Aspen Pharma are no strangers to each other. Glaxo
holds approximately 18.6% of Aspen Pharma's shares (as per Aspen
Pharma's 2012 annual report). Both the companies had entered into
a number of deals in the past.
Last year, Glaxo divested the majority of its Classic Brands in
Australia and non-core over-the-counter (OTC) brands sold in
international markets to Aspen Pharma.
We note that Glaxo's product portfolio was boosted recently with
the approvals of two melanoma drugs, Tafinlar (dabrafenib) and
Mekinist (trametinib) and chronic obstructive pulmonary disease
drug, Breo Ellipta. Moreover, Glaxo boasts of a robust pipeline.
A number of pipeline-related news is expected in the coming
quarters. We believe that the pipeline at Glaxo must deliver to
combat the generic threat faced by the key drugs of the company.
Glaxo carries a Zacks Rank #3 (Hold). Companies that currently
look well-positioned include
). While Biogen and Santarus are Zacks Rank #1 (Strong Buy)
stock, Novo Nordisk is a Zacks Rank #2 (Buy) stock.